Indications
Kepivance is indicated to decrease the incidence, duration and severity of oral mucositis in adult patients with haematological malignancies receiving myeloablative radiochemotherapy associated with a high incidence of severe mucositis and requiring autologous-haematopoietic-stem-cell support.
Composition
- Active substance
- palifermin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kepivance
- Active substance
- palifermin
- ATC code
- V03AF08
- Group
- Various
- Therapeutic area
- Mucositis
- Marketing authorisation holder
- Swedish Orphan Biovitrum AB (publ)
- Status
- Withdrawn